Dr. Chandrashekara S. discusses the therapeutic application and clinical monitoring of Conventional Synthetic DMARDs (csDMARDs) such as Methotrexate, Leflunomide, Sulfasalazine, and Hydroxychloroquine in managing Rheumatoid Arthritis. The session outlines baseline screening, organ-specific toxicity risks (hepatic, renal, and pulmonary), patient monitoring protocols, and evidence-based strategies to mitigate and manage adverse drug reactions in daily rheumatology practice.
